RecruitingPhase 2NCT07023588

Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

Studying Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Yehui Tan
Intervention
Venetoclax(drug)
Enrollment
70 target
Eligibility
18 years · All sexes
Timeline
20252029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07023588 on ClinicalTrials.gov

Other trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

Additional recruiting or active studies for the same condition.

See all trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)

← Back to all trials